title: A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
authors.affiliation: Department of Medicine, New England Medical Center, Boston, MA 02111.
authors.forename: D R
authors.initials: DR
authors.lastname: Snydman
authors.forename: B G
authors.initials: BG
authors.lastname: Werner
authors.forename: N N
authors.initials: NN
authors.lastname: Dougherty
authors.forename: J
authors.initials: J
authors.lastname: Griffith
authors.forename: R H
authors.initials: RH
authors.lastname: Rohrer
authors.forename: R
authors.initials: R
authors.lastname: Freeman
authors.forename: R
authors.initials: R
authors.lastname: Jenkins
authors.forename: W D
authors.initials: WD
authors.lastname: Lewis
authors.forename: E
authors.initials: E
authors.lastname: O'Rourke
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D001900:Boston; D002177:Candidiasis / Q000209:etiology; D002648:Child; D003587:Cytomegalovirus / Q000276:immunology* / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000209:etiology; D010919:Placebos; D011024:Pneumonia, Viral / Q000209:etiology; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D010919:Placebos; C045781:cytomegalovirus-specific hyperimmune globulin; D015774:Ganciclovir; D000212:Acyclovir